$0.01
0.00 (-12.00%)
BTAI News3 articles
BioXcel Surges 8% as 143M Shares Trade Ahead of Nasdaq Delisting
BioXcel shares jumped 8% with 143M shares traded ahead of Nasdaq delisting. The surge reflects distressed asset trading as Teva's $57.5M bid moves forward.
BioXcel Plunges 75% as Teva Stalking-Horse Bid and Chapter 11 Filing Shake Investors
BioXcel shares collapsed 74.8% after bankruptcy filing; Teva offers $57.5M for assets, but equity holders face near-total loss.
BioXcel Therapeutics Files Chapter 11; Shares Plunge 62%
BioXcel Therapeutics (BTAI) filed for Chapter 11 bankruptcy, sending shares down 62.4% to $0.27. The company's liabilities ($100M-$500M) far exceed its assets ($10M-$50M), leaving common equity subordinate.